EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Quest Diagnostics Incorporated (Q1UE34) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Quest Diagnostics Incorporated BRL 402, price BRL 580, upside -30.6%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · ISIN US74834L1008

QD Broad data Sep 29, 2026

Quest Diagnostics Incorporated

Q1UE34 · SA

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value R$402.43 · Overvalued (−30.6%)
✓Quality 66/100
✓Healthy Growth (revenue 3y +3.7 %/yr)
!Thin margins · 9.1% net margin (TTM)
✓Moderate debt · generates free cash flow
✓0.6% dividend yield · Well covered
!Moderate moat 54/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$613.80 R$290.59 Fair Value R$402.43 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.

How to read this chart

60‑month range R$290.59 – R$613.80 · fair‑value band R$233.24 – R$591.45 · the R$579.60 price screens above the R$402.43 fair value. Dashed = 300-day average. As of Sep 29, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Show more

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Stock analysis

Quest Diagnostics Incorporated (Q1UE34) currently trades at R$579.60, while our model-based Fair Value estimate is R$402.43, 30.6% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of R$467.31 per share, and 2 of the 26 models we run sit above the R$579.60 price.

Bear case: the Asset-Based group reads lowest at R$113.32, and 24 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: R$233.24 (bear) to R$591.45 (bull), the price of R$579.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Quest Diagnostics Incorporated reported revenue of $11.0B in FY2025 versus $9.9B in FY2022, a compound +3.7%/yr. Reported net income was $992M in FY2025, compounding +1.6%/yr from FY2022.

Key figures

Market cap R$125B (≈ $23.9B) · P/E ratio 24.7 · P/S ratio 2.22 · EPS (TTM) R$23.44 · Dividend yield 0.6% · Net margin 9.0% · Return on equity 14.5% · Return on assets (EBIT) 9.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −31%, Q1UE34 screens richer than that median.

Fair Value models

Bear R$233.24 Fair Value R$402.43 Bull R$591.45
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$15.26 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF R$313.61 R$556.34 R$929.61 75
Growth DCF R$320.37 R$534.16 R$842.24 74
Residual Income R$164.54 R$203.72 R$294.35 72
All 26 models by family
DCF Models
FCF DCF R$313.61 R$556.34 R$929.61 75
Owner Earnings R$226.22 R$419.11 R$715.72 71
5Y Revenue Exit R$244.06 R$445.93 R$702.14 68
5Y EBITDA Exit R$342.34 R$630.82 R$967.61 70
5Y P/E Exit R$260.51 R$476.87 R$703.30 67
10Y Revenue Exit R$254.91 R$445.76 R$700.28 63
10Y EBITDA Exit R$327.95 R$574.53 R$903.99 64
10Y P/E Exit R$275.67 R$467.31 R$701.17 60
Earnings-Based
Graham-Dodd R$159.12 R$508.84 R$678.55 62
Lynch FV R$112.53 R$160.76 R$208.98 58
PEG = 1.0 R$112.53 R$160.76 R$208.98 55
EPV R$164.18 R$210.20 R$250.47 71
Dividend Discount
Gordon GGM R$76.45 R$158.96 R$252.18 63
DDM Multi-Stage R$76.45 R$127.98 R$166.84 64
Multiples
P/E Multiple R$386.09 R$514.79 R$643.49 63
P/S Multiple R$298.35 R$397.79 R$497.24 58
P/B Multiple R$298.35 R$397.79 R$497.24 55
EV/EBIT R$356.00 R$511.99 R$667.98 65
EV/EBITDA R$414.59 R$590.11 R$765.63 67
EV/Revenue R$222.03 R$365.17 R$508.32 52
Asset-Based
NCAV (Graham) R$84.56 R$113.32 R$169.13 54
Growth DCF
Growth DCF R$320.37 R$534.16 R$842.24 74
Rev-Margin DCF R$244.06 R$447.53 R$683.73 68
Economic Profit
Residual Income R$164.54 R$203.72 R$294.35 72
ROIC Compounder R$164.18 R$234.82 R$329.28 68
Growth Earnings
Growth-Adj P/E R$320.67 R$458.09 R$595.52 65

Open the full fair value analysis →

Notify me when Q1UE34 reaches fair value

Put Q1UE34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 66/100

Of which business quality 63 · Market factors (momentum, volatility) 73

Profitability 46
Margins and returns on capital today
Quality Growth 62
Are margins and returns improving?
Cashflow 69
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 70
Disciplined investing over empire-building
Low Volatility 95
Calm price path (market factor)
Momentum 61
Price trend over the last 3–12 months (market factor)
52W Momentum 67
Distance to the 52-week high (market factor)
Net Issuance 88
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 71/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.6%
Dividend (yield on the price)0.6%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 14%

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.0% a year for the price and +2.2% for the forecasts.
Forecast 2026 (sales)+7.4%
Forecast 2027 (sales)+4.4%
Projected 2028 (sales)+4.1%
Projected 2029 (sales)+3.8%
Projected 2030 (sales)+3.5%

Q1UE34 screens overvalued: fair value 31% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Quest Diagnostics Incorporated with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 565.60 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Quest Diagnostics Incorporated · Fair Value
R$402.43 −31%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Quest Diagnostics Incorporated Fair Value". https://www.fairvalue-calculator.com/stock/Q1UE34

Frequently asked questions

Is Quest Diagnostics Incorporated (Q1UE34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$402.43 versus a price of R$579.60, about −31% upside (overvalued).
What is the fair value of Q1UE34?
Our model-based fair value for Quest Diagnostics Incorporated is R$402.43 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$579.60.
What is the quality score of Q1UE34?
Quest Diagnostics Incorporated has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Quest Diagnostics Incorporated (Q1UE34)?
Our model-based price target is the fair value of R$402.43 (as of Sep 29, 2026) from 26 valuation models. Cautious scenario R$233.24, optimistic scenario R$591.45. It is a calculation from audited fundamentals, not an analyst target.
What is the Quest Diagnostics Incorporated stock forecast for 2026?
Our models put fair value at R$402.43, about −31% upside versus a price of R$579.60 (overvalued). Cautious scenario R$233.24, optimistic scenario R$591.45. The calculation is refreshed regularly with new filings.
What is the revenue of Quest Diagnostics Incorporated (Q1UE34)?
Quest Diagnostics Incorporated reported trailing-twelve-month revenue of about $11.3B (latest available figure, as of Sep 29, 2026).
Does Quest Diagnostics Incorporated pay a dividend?
Quest Diagnostics Incorporated currently shows a dividend yield of about 0.56% relative to its recent price (as of Sep 29, 2026).
What growth is priced into Quest Diagnostics Incorporated (Q1UE34)?
For today's price to be fair in a discounted-cash-flow model, Quest Diagnostics Incorporated would have to grow free cash flow by +4.4 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +3.7 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of Q1UE34 use?
Our models discount Quest Diagnostics Incorporated at 10.9 %: a base by market capitalisation (large), damped by beta 0.57, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Quest Diagnostics Incorporated that is +4.4 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Quest Diagnostics Incorporated (Q1UE34) delivered so far?
Over the past 3 years revenue at Quest Diagnostics Incorporated grew +3.7 % a year. The price currently implies +4.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Quest Diagnostics Incorporated (Q1UE34) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into Quest Diagnostics Incorporated (+4.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Quest Diagnostics Incorporated (Q1UE34)?
The free-cash-flow yield on the price is 11.13 %: that much free cash flow Quest Diagnostics Incorporated produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Quest Diagnostics Incorporated (Q1UE34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Quest Diagnostics Incorporated it is R$402.43 per share (as of Sep 29, 2026), against a price of R$579.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Quest Diagnostics Incorporated stock overvalued or undervalued in 2026?
As of Sep 29, 2026, Q1UE34 trades above its calculated fair value: price R$579.60, fair value R$402.43, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of Q1UE34?
No. The price is what the market pays today (R$579.60); the fair value is what the company's own numbers justify (R$402.43). For Quest Diagnostics Incorporated the two are R$177.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Quest Diagnostics Incorporated worth?
The market values Quest Diagnostics Incorporated at about R$125B (market capitalisation, as of Sep 29, 2026). Per share that is R$579.60; our models calculate a fair value of R$402.43 per share.
What do the bullish and bearish scenarios say about Q1UE34?
Our models span a range for Quest Diagnostics Incorporated: cautious scenario R$233.24, base R$402.43, optimistic R$591.45 per share (as of Sep 29, 2026, price R$579.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is Q1UE34 from its 52-week high?
Quest Diagnostics Incorporated trades at R$579.60, about 6% below its 52-week high of R$613.80 and 22% above the low of R$475.52 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of R$402.43 is for.
Which stocks are comparable to Quest Diagnostics Incorporated?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Quest Diagnostics Incorporated stock attractive at the current price?
The data as of Sep 29, 2026: price R$579.60, calculated fair value R$402.43 (−31%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of Q1UE34 calculated?
We run Quest Diagnostics Incorporated through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$402.43, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Quest Diagnostics Incorporated itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Quest Diagnostics Incorporated (Q1UE34)?
The closing price on Oct 1, 2026 was R$579.60. Our model-based fair value is R$402.43, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Quest Diagnostics Incorporated right now?
Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (R$233.24 to R$591.45) leaves room in how you read the outcome.

Key figures of Quest Diagnostics Incorporated

How large is the market capitalisation of Quest Diagnostics Incorporated (Q1UE34)?
The market capitalisation of Quest Diagnostics Incorporated is R$125B (≈ $23.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Quest Diagnostics Incorporated (Q1UE34)?
The price-to-earnings ratio of Quest Diagnostics Incorporated is 24.7. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Quest Diagnostics Incorporated (Q1UE34)?
The price-to-sales ratio of Quest Diagnostics Incorporated is 2.22 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Quest Diagnostics Incorporated (Q1UE34)?
Earnings per share at Quest Diagnostics Incorporated are R$23.44 (price ÷ EPS = P/E 24.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Quest Diagnostics Incorporated (Q1UE34)?
The dividend yield of Quest Diagnostics Incorporated is 0.6% (payout 13.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Quest Diagnostics Incorporated (Q1UE34)?
The net margin of Quest Diagnostics Incorporated is 9.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Quest Diagnostics Incorporated (Q1UE34)?
The return on equity (ROE) of Quest Diagnostics Incorporated is 14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Quest Diagnostics Incorporated (Q1UE34)?
On an EBIT basis the return on assets of Quest Diagnostics Incorporated is 9.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Quest Diagnostics Incorporated (Q1UE34)?
The operating margin of Quest Diagnostics Incorporated is 14.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Quest Diagnostics Incorporated (Q1UE34)?
Revenue at Quest Diagnostics Incorporated is growing +9.2% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Quest Diagnostics Incorporated (Q1UE34)?
Earnings per share at Quest Diagnostics Incorporated are growing +15.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Quest Diagnostics Incorporated (Q1UE34) carry?
The net debt of Quest Diagnostics Incorporated is $5.5B (fiscal year 2025, ≈ 4.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.